Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...